0.81
+0.0132(+1.66%)
Currency In USD
| Previous Close | 0.79 |
| Open | 0.79 |
| Day High | 0.83 |
| Day Low | 0.79 |
| 52-Week High | 1.65 |
| 52-Week Low | 0.7 |
| Volume | 87,124 |
| Average Volume | 243,885 |
| Market Cap | 62.63M |
| PE | -1.97 |
| EPS | -0.41 |
| Moving Average 50 Days | 0.82 |
| Moving Average 200 Days | 0.98 |
| Change | 0.01 |
If you invested $1000 in Clearside Biomedical, Inc. (CLSD) since IPO date, it would be worth $111.17 as of July 03, 2025 at a share price of $0.806. Whereas If you bought $1000 worth of Clearside Biomedical, Inc. (CLSD) shares 5 years ago, it would be worth $421.99 as of July 03, 2025 at a share price of $0.806.
For more details, use our stock calculator to calculate how much you would've made investing different amounts on specific dates.
Clearside Biomedical Announces Multiple Presentations to be Featured at the Clinical Trials at the Summit Meeting
GlobeNewswire Inc.
Jun 17, 2025 11:05 AM GMT
- Broad Use of Suprachoroidal Injection Platform Highlighted Across Retinal Indications - - CLS-AX Combines the Flexibility of Anti-VEGF Therapies with the Long-Lasting Benefits of a Tyrosine Kinase Inhibitor - ALPHARETTA, Ga., June 17, 2025 (GLOBE
Clearside Biomedical to Participate in a Fireside Chat at the Stifel 2025 Virtual Ophthalmology Forum
GlobeNewswire Inc.
May 21, 2025 11:05 AM GMT
ALPHARETTA, Ga., May 21, 2025 (GLOBE NEWSWIRE) -- Clearside Biomedical, Inc. (Nasdaq: CLSD), a biopharmaceutical company revolutionizing the delivery of therapies to the back of the eye through the suprachoroidal space (SCS®), announced today that
Clearside Biomedical Announces First Quarter 2025 Financial Results and Provides Corporate Update
GlobeNewswire Inc.
May 14, 2025 8:05 PM GMT
- Successful End-of-Phase 2 Meeting with FDA Led to Alignment on Phase 3 Program Design for CLS-AX in Wet AMD - - CLS-AX Targets Commercially Attractive Product Profile with Three-to-Six Month Flexible Maintenance Dosing - - Multiple Milestones Achie